Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Operating Expenses (2019 - 2025)

Eton Pharmaceuticals' Operating Expenses history spans 7 years, with the latest figure at $9.2 million for Q3 2025.

  • For Q3 2025, Operating Expenses rose 59.12% year-over-year to $9.2 million; the TTM value through Sep 2025 reached $38.8 million, up 50.46%, while the annual FY2024 figure was $26.0 million, 16.87% up from the prior year.
  • Operating Expenses for Q3 2025 was $9.2 million at Eton Pharmaceuticals, down from $13.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $13.4 million in Q2 2025 and bottomed at $4.4 million in Q4 2021.
  • The 5-year median for Operating Expenses is $5.8 million (2024), against an average of $6.5 million.
  • The largest annual shift saw Operating Expenses tumbled 44.31% in 2021 before it soared 77.91% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $4.4 million in 2021, then grew by 20.22% to $5.3 million in 2022, then rose by 6.13% to $5.6 million in 2023, then grew by 3.98% to $5.8 million in 2024, then skyrocketed by 57.65% to $9.2 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Operating Expenses are $9.2 million (Q3 2025), $13.4 million (Q2 2025), and $10.3 million (Q1 2025).